Neuberger Berman Group
ADMA icon

Neuberger Berman Group’s ADMA Biologics ADMA Stock Holding History

Neuberger Berman Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$117K Sell
12,937
-368,848
-97% -$5.82M ﹤0.01% 2058
2025
Q4 		$6.96M Sell
381,785
-131,479
-26% -$2.22M 0.01% 896
2025
Q3 		$7.52M Buy
513,264
+86,239
+20% +$1.48M 0.01% 867
2025
Q2 		$7.78M Buy
427,025
+413,847
+3,140% +$8.44M 0.01% 850
2025
Q1 		$261K Buy
+13,178
New +$228K ﹤0.01% 1740
2024
Q3 		– Sell
-12,247
Closed -$137K – 1928
2024
Q2 		$137K Buy
+12,247
New +$103K ﹤0.01% 1791

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Neuberger Berman Group's ADMA Position: Q1 2026 in Review

Neuberger Berman Group reduced its ADMA Biologics (ADMA) stake by 97% in Q1 2026, selling an estimated $5.82M and leaving 12,937 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #2058.

Neuberger Berman Group first reported a position in ADMA in Q2 2024 and has held it in 6 quarters since. The position peaked at $7.78M in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Neuberger Berman Group held 12,937 shares of ADMA Biologics worth $117K as of Q1 2026.
  • Neuberger Berman Group sold 368,848 ADMA Biologics shares in Q1 2026, an estimated $5.82M.
  • ADMA Biologics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #2058 holding.
  • Neuberger Berman Group first reported a position in ADMA Biologics in Q2 2024 and has held it in 6 quarters since.
  • Neuberger Berman Group's ADMA Biologics position peaked at $7.78M in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.